Shares of ARCA biopharma Inc. (ABIO) are rising over 108% in pre-market today, after the company announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor or TF, as a potential treatment for COVID-19 associated coagulopathy or CAC and the related inflammatory response.
from RTT - Before the Bell https://ift.tt/3c5p41C
via IFTTT
No comments:
Post a Comment